Teva Pharmaceutical Industries Limited (TEVA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Teva Pharmaceutical Industries Limited (TEVA) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (61/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+153.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How TEVA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | 51.8% | 12.5% | $1.41B | $872.4M | 8.9% |
| FY 2024 | $16.54B | 48.7% | -1.8% | -$1.64B | $502.5M | -1.4% |
| FY 2023 | $15.85B | 44% | 2.7% | -$559.0M | $654.9M | 2.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TEVA)
- ✓Live walkthrough of TEVA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
TEVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TEVA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TEVA. Explore sector supply chains on /butterfly.
TEVA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Teva Pharmaceutical Industries Limited (TEVA)?
In FY 2025 (10-K), TEVA converted $17.3B of revenue into a 51.8% gross margin, 12.5% operating margin, and $872.4M in free cash flow (5.1% FCF margin).